Monoamine Oxidase Inhibitors

A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)
DrugDrug NameDrug Indication
DB00752TranylcypromineFor the treatment of major depressive episode without melancholia.
DB00780PhenelzinePhenelzine is indicated for the treatment of nonendogenous, neurotic or atypical depression for patients that do not tolerate other forms of therapy.[L1356] Atypical depression has a high prevalence rate, starts in early life, tends to last longer, is more likely to occur in people with bipolar disorder, has a high comorbidity with anxiety disorder and carries more risk of suicidal behavior. It is important to specify the atypical feature to predict the clinical course of depression and hence generate the best treatment and service. The featuring symptoms of the atypical feature include mood reactivity, two or more of this symptoms: 1) increased appetite, 2) increased sleep, 3) leaden paralysis and 4) interpersonal rejection sensitivity and should not have melancholic or catatonic features of depression.[A31917] Neurotic depression is a depression of an emotionally unstable person. It is a secondary condition to major personality disorder, neuroses and drug use disorders. Likewise, a primary depression with a family history of depression spectrum disease would fit in this category.[A31922] A nonendogenous depression is characterized by a disturbance in mood and general outlook. The physical symptoms tend to be less severe and it often occurs in response to stressful life events that keep occurring over a large period of time generating a continuous stress in the daily living.[A31924]
DB01037SelegilineMonotherapy for initial treatment of Parkinson's disease, as well as an adjunct therapy in patients with a decreased response to levodopa/carbadopa. Also used for the palliative treatment of mild to moderate Alzheimer's disease and at higher doses, for the treatment of depression.
DB01171MoclobemideFor the treatment of major depressive disorder and bipolar disorder [A31901].
DB01247IsocarboxazidIsocarboxazid is indicated for the treatment of the enduring and debilitating symptoms of depression that have not responded to other antidepressant drugs.[L1372] Depression is a common but serious mood disorder. The patient will present changes in its feelings, thoughts, and ability to handle everyday activities. For a mood disorder to be considered as depression, the symptoms should be present for at least two weeks.[L1375]
DB01367RasagilineFor the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
DB01626PargylineFor the treatment of moderate to severe hypertension.
DB00805MinaprineFor the treatment of depression
DB04818IproniazidFor the treatment of depression (originally intended to treat tuberculosis).
DB04820NialamideNot Available
DB09244PirlindoleFor the treatment of major depression. It is being studied in the treatment of fibromyalgia pain syndrome. One study determined that the effect of pirlindole on sensorimotor performance while driving a motor vehicle shows many similarities to that of placebo. The drug appears to stimulate the central nervous system, rather than exhibit a sedative effect, like many antidepressants. Because of its selective, reversible inhibition of monoamine oxidase (MAO-A) and short half-life, unpleasant "cheese effects" are avoided. This refers to the effects of consuming tyramine-rich foods, such as cheese while medicated with monoamine oxidase inhibitors, leading to severe headaches and hypertension [L1395]. of The available evidence supports pirlindole as a safe and effective treatment option for the management of depression and fibromyalgia syndrome [L1394].
DB09245ToloxatoneFor the treatment of major depressive disorder.
DB09243HydracarbazineWas used for the treatment of hypertension [A19790].
DB09241Methylene blueMethylene blue has several indications in medicine: 1. found to improve the hypotension associated with various clinical states. 2. Antiseptic in urinary tract infections. 3. Improves hypoxia and hyper dynamic circulation in cirrhosis of liver and severe hepatopulmonary syndrome. 4. Results in transient and reproducible improvement in blood pressure and cardiac function in septic shock. 5. Investigated for the treatment of Alzheimer's disease. 6. Treatment of ifofosamide induced neurotoxicity.
DB09246BenmoxinFor the treatment of depression.
DB09248MebanazineFor the treatment of depression.
DB09249OctamoxinFor the treatment of depression.
DB09250PheniprazineFor the treatment of depression, schizophrenia, and angina pectoris.
DB09251PhenoxypropazineFor the treatment of depression.
DB09252PivhydrazineFor the treatment of depression.
DB09253SafrazineFor the treatment of depression.
DB09254CaroxazoneFor the treatment of depression.
DB00614FurazolidoneFor the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms.
DB085507,8-Dichloro-1,2,3,4-tetrahydroisoquinolineNot Available
DB13875HarmalineNot Available
DB13876BrofaromineNot Available
DB00721ProcaineUsed as a local anesthetic primarily in oral surgery
DB00182AmphetamineAmphetamine is indicated for the treatment of attention-deficit/hyperactivity disorders (ADHD) as well as for the treatment of central nervous system disorders such as narcolepsy.[A18540] ADHD is a complex disorder associated with the substantial heterogeneity in etiology, clinical presentation, and treatment outcome. ADHD comes from a complex interplay between interdependent genetic and non-genetic factors which cause complex mental disorders in children and teenagers.[A174271] On the other hand, narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepiness.[A174274] Amphetamine is also being used nowadays off-label for the treatment of obesity, depression and chronic pain.[A174268, A174283]
DB01168ProcarbazineFor use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease.
DB00601LinezolidFor the treatment of bacterial infections caused by susceptible strains of vancomycin resistant Enterococcus faecium, Staphylococcal aureus (methicillin resistant and susceptible strains), Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae.
DB06654SafinamideSafinamide is indicated as an add-on treatment to levodopa with or without other medicines for Parkinson’s disease
DB04017ClorgilineNot Available
DrugDrug NameTargetType
DB00752TranylcypromineAmine oxidase [flavin-containing] Btarget
DB00752TranylcypromineAmine oxidase [flavin-containing] Atarget
DB00752TranylcypromineCytochrome P450 2C19enzyme
DB00752TranylcypromineCytochrome P450 2A6enzyme
DB00752TranylcypromineCytochrome P450 2D6enzyme
DB00752TranylcypromineCytochrome P450 1A2enzyme
DB00752TranylcypromineCytochrome P450 2C9enzyme
DB00752TranylcypromineCytochrome P450 2E1enzyme
DB00752TranylcypromineCytochrome P450 3A4enzyme
DB00780PhenelzineMembrane primary amine oxidasetarget
DB00780PhenelzineAmine oxidase [flavin-containing] Btarget
DB00780PhenelzineAmine oxidase [flavin-containing] Atarget
DB00780PhenelzineAmine oxidase [flavin-containing] Aenzyme
DB00780PhenelzineAmine oxidase [flavin-containing] Benzyme
DB00780PhenelzineCytochrome P450 2E1enzyme
DB00780Phenelzine4-aminobutyrate aminotransferase, mitochondrialtarget
DB00780PhenelzineGlutamic acid decarboxylasetarget
DB00780PhenelzineAlanine aminotransferase 1target
DB00780PhenelzineAlanine aminotransferase 2target
DB00780PhenelzineCytochrome P450 2C19enzyme
DB00780PhenelzineCytochrome P450 2C8enzyme
DB00780PhenelzineCytochrome P450 3A4enzyme
DB00780PhenelzineCytochrome P450 3A43enzyme
DB00780PhenelzineCytochrome P450 3A5enzyme
DB00780PhenelzineCytochrome P450 3A7enzyme
DB00780PhenelzineCytochrome P450 2D6enzyme
DB01037SelegilineAmine oxidase [flavin-containing] Btarget
DB01037SelegilineCytochrome P450 2B6enzyme
DB01037SelegilineAmine oxidase [flavin-containing] Atarget
DB01037SelegilineCytochrome P450 2A6enzyme
DB01037SelegilineCytochrome P450 3A4enzyme
DB01037SelegilineMultidrug resistance protein 1transporter
DB01037SelegilineCytochrome P450 1A2enzyme
DB01037SelegilineCytochrome P450 2C19enzyme
DB01037SelegilineCytochrome P450 2C8enzyme
DB01037SelegilineCytochrome P450 2C9enzyme
DB01037SelegilineCytochrome P450 2D6enzyme
DB01037SelegilineCytochrome P450 2E1enzyme
DB01171MoclobemideAmine oxidase [flavin-containing] Atarget
DB01171MoclobemideCytochrome P450 2C19enzyme
DB01171MoclobemideCytochrome P450 2D6enzyme
DB01171MoclobemideAmine oxidase [flavin-containing] Aenzyme
DB01171MoclobemideAmine oxidase [flavin-containing] Benzyme
DB01171MoclobemideCytochrome P450 2C9enzyme
DB01171MoclobemideMonoamine oxidasetarget
DB01171MoclobemideAmine oxidase [flavin-containing] Btarget
DB01247IsocarboxazidAmine oxidase [flavin-containing] Atarget
DB01247IsocarboxazidAmine oxidase [flavin-containing] Btarget
DB01367RasagilineApoptosis regulator Bcl-2target
DB01367RasagilineAmine oxidase [flavin-containing] Btarget
DB01367RasagilineCytochrome P450 1A2enzyme
DB01626PargylineAmine oxidase [flavin-containing] Btarget
DB01626PargylineAmine oxidase [flavin-containing] Atarget
DB00805MinaprineD(1A) dopamine receptortarget
DB00805MinaprineD(2) dopamine receptortarget
DB00805Minaprine5-hydroxytryptamine receptor 2Atarget
DB00805Minaprine5-hydroxytryptamine receptor 2Btarget
DB00805Minaprine5-hydroxytryptamine receptor 2Ctarget
DB00805MinaprineSodium-dependent serotonin transportertarget
DB00805MinaprineCytochrome P450 2D6enzyme
DB00805MinaprineMuscarinic acetylcholine receptor M1target
DB00805MinaprineAmine oxidase [flavin-containing] Atarget
DB04818IproniazidAmine oxidase [flavin-containing] Benzyme
DB04818IproniazidCytochrome P450 2D6enzyme
DB04818IproniazidCytochrome P450 2C9enzyme
DB04820NialamideAmine oxidase [flavin-containing] Btarget
DB04820NialamideAmine oxidase [flavin-containing] Atarget
DB04820NialamideCatechol O-methyltransferasetarget
DB09244PirlindoleAmine oxidase [flavin-containing] Atarget
DB09244Pirlindole5-hydroxytryptamine receptor 1Atarget
DB09244PirlindoleAlpha-2A adrenergic receptortarget
DB09244PirlindoleAmine oxidase [flavin-containing] Aenzyme
DB09245ToloxatoneAmine oxidase [flavin-containing] Atarget
DB09245ToloxatoneAmine oxidase [flavin-containing] Aenzyme
DB09241Methylene blueGuanylate cyclase soluble subunit alpha-2target
DB09241Methylene blueNitric oxide synthase, braintarget
DB00614FurazolidoneAmine oxidase [flavin-containing] Benzyme
DB00614FurazolidoneAmine oxidase [flavin-containing] Aenzyme
DB085507,8-Dichloro-1,2,3,4-tetrahydroisoquinolinePhenylethanolamine N-methyltransferasetarget
DB13875HarmalineHistamine N-methyltransferasetarget
DB13876BrofaromineAmine oxidase [flavin-containing] Atarget
DB00721ProcaineSodium channel protein type 10 subunit alphatarget
DB00721ProcaineGlutamate receptor ionotropic, NMDA 3Atarget
DB00721Procaine5-hydroxytryptamine receptor 3Atarget
DB00721ProcaineSodium-dependent dopamine transportertarget
DB00721ProcaineNeuronal acetylcholine receptor subunit alpha-2target
DB00721ProcaineCalcium-activated potassium channeltarget
DB00721ProcainePhospholipase A2target
DB00721ProcaineMonoamine oxidasetarget
DB00182AmphetamineSodium-dependent dopamine transportertarget
DB00182AmphetamineCocaine- and amphetamine-regulated transcript proteintarget
DB00182AmphetamineTrace amine-associated receptor 1target
DB00182AmphetamineCytochrome P450 2D6enzyme
DB00182AmphetamineSolute carrier family 22 member 3transporter
DB00182AmphetamineSolute carrier family 22 member 5transporter
DB00182AmphetamineSynaptic vesicular amine transportertarget
DB00182AmphetamineCytochrome P450 2A6enzyme
DB00182AmphetamineSodium-dependent noradrenaline transportertarget
DB00182AmphetamineAlpha adrenergic receptortarget
DB00182AmphetamineBeta adrenergic receptortarget
DB00182AmphetamineD(2) dopamine receptortarget
DB00182AmphetamineAmine oxidase [flavin-containing] Btarget
DB00182AmphetamineSodium-dependent serotonin transportertarget
DB00182AmphetamineMonoamine oxidasetarget
DB00182Amphetaminevesicular monoamine transporter 2 (VMAT2)target
DB01168ProcarbazineXanthine dehydrogenase/oxidaseenzyme
DB01168ProcarbazineCytochrome P450 1B1enzyme
DB01168ProcarbazineMonoamine oxidasetarget
DB00601Linezolid23S rRNAtarget
DB00601LinezolidAmine oxidase [flavin-containing] Aenzyme
DB00601LinezolidAmine oxidase [flavin-containing] Benzyme
DB06654SafinamideAmine oxidase [flavin-containing] Btarget
DB06654SafinamideAmine oxidase [flavin-containing] Aenzyme
DB06654SafinamideATP-binding cassette sub-family G member 2transporter
DB06654SafinamideSolute carrier organic anion transporter family member 3A1transporter
DB06654SafinamideCytochrome P450 3A4enzyme
DB06654SafinamideCytochrome P450 1A1enzyme
DB06654SafinamideCytochrome P450 1A2enzyme
DB06654SafinamideCytochrome P450 2B6enzyme
DB06654SafinamideCytochrome P450 2C9enzyme
DB06654SafinamideCytochrome P450 2D6enzyme
DB06654SafinamideCytochrome P450 2C19enzyme
DB06654SafinamideCytochrome P450 2E1enzyme
DB06654SafinamideCytochrome P450 3A5enzyme
DB04017ClorgilineAmine oxidase [flavin-containing] Atarget